Clinical trial · Observational
Exosome-based Recurrence Score for Post-Treatment Ovarian Cancer
Exosome-based Scoring Model for Post-treatment Surveillance of Recurrence in Ovarian Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this observational study is to develop an exosome-based scoring model for post-treatment surveillance of recurrence in ovarian cancer. The main questions it aims to answer are: 1. Does this model have the potential for ovarian cancer recurrence monitoring? 2. Can this model demonstrate superior performance to CA125 for ovarian cancer recurrence monitoring? Participants will : 1. Provide serial blood samples at predefined times 2. Undergo standardized imaging and clinical assessments during follow-up visits
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Not applicable- observational study | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Single Cohort
- interventionNames
- Other: Not applicable- observational study
Primary outcomes (1)
- measure
- Recurrence-free survival
- timeFrame
- From the end of adjuvant threapy to the end of follow-up visits at 18 months
- description
- The length of time from the date of the end of adjuvant threapy to the date of the first loco-regional or systemic recurrence
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Women aged ≥ 18 years * Pathologic confirmed stage I-IV epithelial ovarian cancer, with ≤2 prior lines of therapy (maintenance therapy is not counted as a line of treatment), platinum-sensitive recurrence (achieved complete/partial response \[CR/PR\] after last platinum-based chemotherapy, with a platinum-free interval \>6 months), and radiologically confirmed recurrent disease * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 * A life expectancy of at least 6 months * Written informed consent Exclusion Criteria: * Patients with non-epithelial tumors * Patients with history of other malignancies within the past 5 years (except completely resected basal cell carcinoma or squamous cell carcinoma of the skin) * Women who are pregnant, lactating, or intend to become pregnant during the study period * Patients who refuse to participate in the study
References
Publications (0)
Data not yet available